petct3_side.jpg

THERAPEUTICS & DIAGNOSTICS

BioMolecular Imaging has extensive, decades-long experience in anatomic and molecular imaging as applied to the conduct of therapeutic trials and the determination of drug efficacy. The design and development of new diagnostic agent is a related area of knowledge and experience. This spans most all imaging modalities, organ systems, and therapeutic areas. Trial design, data analysis, and expert image reads are areas of expertise.

ONCOLOGY

Imaging in cancer is an increasing component of BioMolecular Imaging consultancy activities, including the use of small molecule, antibody and peptide imaging technologies. We can help your company in all aspects of cancer imaging, including probe molecule choice, isotope selection, GMP manufacturing, protocol preparation, site selection, and image analysis, including tracer kinetic modeling. Anatomic imaging with, for example, CT and MR imaging is also an area of deep knowledge, whether conducted alone or in conjunction with molecular imaging

BRAIN

CNS imaging is a core area of expertise and experience, going back to the early beginning of molecular imaging when Jim and his group developed some of the very first molecular brain imaging technologies. BioMolecular Imaging can advise and assist your company on small molecule imaging projects across diverse areas, including dementia, movement disorders, mental illness, addiction, cancer, and inflammation.

BIOMARKERS

A very active area of current investigation and commercialization is molecular and functional biomarker development. These biomarkers can serve as surrogate endpoints for therapeutic efficacy and are increasingly viewed by the FDA as highly desirable. Attractive features are reduced trial size, shortened completion time, and reduced cost. Biomarkers can also be extended to use as diagnostic agents, either as stand-alone probes or in combination with therapeutic drugs in order to stratify patients for treatment and outcome monitoring.

CARDIOLOGY

Molecular, functional, and anatomic cardiovascular imaging continues to be a topic of increasing interest in diagnostics and drug development, especially as related to obesity and metabolic disease. BioMolecular Imaging possesses knowledge and experience across the conventional radiologic and nuclear medicine imaging technologies and has had direct involvement in cardiovascular molecular imaging, for example in receptor and in membrane potential imaging. We can assist your company in all aspects of early and late phase cardiovascular imaging.

CENTRAL IMAGE INTERPRETATION

Jim has extensive experience in central image reads for clinical trials. He is board certified in radiology and in nuclear medicine, and therefore is able to cover most all imaging technologies and disease settings. Due to the structure of BioMolecular Imaging, Jim has the latitude and flexibility to commit to and schedule study reads lasting for a year or longer. Importantly, in past reads Jim has been able to always meet read timelines or complete assigned reads ahead of time, thus providing a major advantage to sponsors in timely trial completion and analysis.

 
 

We reached out to BioMolecular Imaging and Dr. Frost in the process of taking a new imaging agent from preclinical to clinical imaging. Dr. Frost identified several academic imaging institutions for the work and he did the initial vetting from the standpoint of capabilities and timing.

 
Business Meeting

ESSENTIALS

Molecular and anatomic imaging continues to be an ever increasing and essential component of clinical drug trials. Early stage trials examine target accessibility and drug pharmacokinetics, while later phase studies employ imaging as an early indicator of response or as an efficacy endpoint. New molecular probes from early phase studies become the future diagnostic agents that guide patient stratification for therapy and monitor patient response.

The truly staggering cost of drug development dictates that efficient practices must be employed at every development step. The use of quantifiable and objective imaging endpoints can form the basis of the needed process efficiencies, accelerating development and decreasing costs.

While imaging is an extremely powerful technology, it is a complex process itself. Most companies, however, don’t have the internal imaging expertise required to plan and carry out imaging studies. BioMolecular Imaging can help you to develop your company’s internal strategy; navigate imaging process steps to achieve tactical certainty; interface effectively with the necessary external partners; and maximize power of inference using best practice image analytics.

 

CONTACT BIOMOLECULAR IMAGING

Thanks for submitting!